Oruka Therapeutics (NASDAQ:ORKA) Raised to Hold at Wall Street Zen

Oruka Therapeutics (NASDAQ:ORKA) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Monday.

A number of other analysts also recently weighed in on the stock. Wedbush restated an “outperform” rating and issued a $45.00 target price on shares of Oruka Therapeutics in a report on Friday. Stifel Nicolaus increased their price target on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a report on Friday. UBS Group started coverage on Oruka Therapeutics in a research report on Wednesday, January 7th. They issued a “buy” rating and a $50.00 price target for the company. Barclays boosted their price objective on Oruka Therapeutics from $48.00 to $50.00 and gave the stock an “overweight” rating in a research note on Friday. Finally, Guggenheim restated a “buy” rating and set a $60.00 price objective on shares of Oruka Therapeutics in a research report on Friday. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $56.67.

Oruka Therapeutics Stock Performance

ORKA stock opened at $40.00 on Monday. The firm has a fifty day moving average price of $32.92 and a 200 day moving average price of $27.68. Oruka Therapeutics has a fifty-two week low of $5.49 and a fifty-two week high of $41.19. The firm has a market cap of $1.98 billion, a PE ratio of -21.51 and a beta of -0.38.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.16. On average, equities analysts predict that Oruka Therapeutics will post -3.41 EPS for the current year.

Insider Activity at Oruka Therapeutics

In related news, insider Joana Goncalves sold 7,000 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $32.37, for a total transaction of $226,590.00. Following the transaction, the insider directly owned 34,018 shares in the company, valued at approximately $1,101,162.66. This represents a 17.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last three months, insiders have sold 21,000 shares of company stock worth $663,530. 24.69% of the stock is currently owned by insiders.

Institutional Trading of Oruka Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Financial Enhancement Group LLC bought a new stake in shares of Oruka Therapeutics during the 3rd quarter worth approximately $631,000. Avoro Capital Advisors LLC purchased a new position in Oruka Therapeutics during the 3rd quarter valued at $25,640,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new position in Oruka Therapeutics in the 3rd quarter valued at $296,000. B Group Inc. grew its position in Oruka Therapeutics by 28.8% in the 2nd quarter. B Group Inc. now owns 75,000 shares of the company’s stock valued at $841,000 after acquiring an additional 16,785 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in Oruka Therapeutics by 100.6% in the second quarter. Geode Capital Management LLC now owns 707,406 shares of the company’s stock worth $7,932,000 after purchasing an additional 354,821 shares during the period. Institutional investors own 56.44% of the company’s stock.

Key Stories Impacting Oruka Therapeutics

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Multiple brokerages raised or reaffirmed bullish ratings and lifted price targets (signals of stronger buy-side conviction and potential re-rating of the stock). Benzinga
• Positive Sentiment: Barclays raised its price target to $50 and set an “overweight” rating, implying meaningful upside from current levels. Benzinga
• Positive Sentiment: BTIG reiterated a “buy” and kept a $73 price target, the highest among recent notes, which can attract momentum investors. Benzinga Street Insider
• Positive Sentiment: Stifel Nicolaus raised its target to $72 and maintained a “buy,” reinforcing analyst consensus around significant upside. Benzinga
• Positive Sentiment: Guggenheim reaffirmed a “buy” with a $60 target and Wedbush kept an “outperform” at $45 — additional corroboration from the sell-side. Benzinga
• Positive Sentiment: Oruka reported Q4 results with EPS of ($0.45), beating consensus (($0.61)), which reduces short‑term execution risk and supports the bullish analyst activity. Press Release
• Positive Sentiment: Corporate update: ORKA-001 (EVERLAST-A) 16‑week data now expected in 2Q 2026 after rapid enrollment, with longer-term follow-up in 2H 2026 — an accelerated clinical timetable is a near-term catalyst for valuation. GlobeNewswire

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.